Rakuten Medical Highlights the Preclinical Results of RM-0256 at JCA 2024
Shots:
- The abstract title was, ‘PD-L1 photoimmunotherapy kills immunosuppressive myeloid cells to activate local and systemic antitumor immunity’
- The in vitro study depicted its dual MOA of reducing PD-L1 expressing tumor cells & immunosuppressive cells like TAMs & MDSCs plus systemic immune checkpoint inhibition; in vivo study showed effective tumor growth suppression than anti-PD-L1 Ab alone & saline control in anti-PD-L1 sensitive & resistant mouse tumor models, respectively
- In vivo studies also showed decreased immunosuppressive tumor microenvironment cells & enhanced CD8+ T cell activation to maintain checkpoint inhibition. RM-0256 was well-tolerated when given repeatedly to cynomolgus monkeys in a GLP toxicity study
Ref: Rakuten | Image: Rakuten
Related News: Alopexx Partners with Bharat Biotech to Co-Develop and Commercialize AV0328 Anti-Microbial Vaccine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.